Ototoxicity after platinum-based chemotherapy in the treatment of melanotic neuroectodermal tumour of infancy

Oncol Lett. 2020 May;19(5):3411-3416. doi: 10.3892/ol.2020.11447. Epub 2020 Mar 5.

Abstract

Melanotic neuroectodermal tumor of infancy (MNTI) is a rare infantile tumor that originates from mesenchymal-neuroectodermal cells, the treatment of which uses platinum derivatives that can affect hearing loss. The present study evaluated the long-term effects of ototoxicity following chemotherapy with cisplatin, vincristine, cyclophosphamide, teniposide and adriamycin in a 10-year-old patient after surgical removal of a MNTI tumor at the age of 8 months. Audiometric tests (high-frequency tonal audiometry, speech audiometry, speech acoustics, tympanometry and absorbance measurements) were performed during a 10-year follow-up after receiving chemotherapy. Hearing disorders in the high-frequency range (6,000 to 16,000 Hz range) were demonstrated for both ears, indicating that these may be the long-term effects of chemotherapy with use of platinum compounds during the treatment of infants.

Keywords: cisplatin; hearing impairment; melanotic neuroectodermal tumor of infancy; oncological treatment; oncology.